Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

The epidermal growth factor receptor (EGFR) is expressed in the majority of non-small-cell lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to treatment with the EGFR tyrosine kinase inhibitor (EGFR TKI) gefitinib. Clinical trials have demonstrated that patients car...

Descripción completa

Detalles Bibliográficos
Autores principales: Carotenuto, Pietro, Roma, Cristin, Rachiglio, Anna Maria, Pasquale, Raffaella, Franco, Renato, Antinolfi, Giuseppe, Piantedosi, Francovito, Illiano, Alfonso, Botti, Gerardo, Morabito, Alessandro, Normanno, Nicola, De Luca, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513216/
https://www.ncbi.nlm.nih.gov/pubmed/23226050
http://dx.doi.org/10.2147/PGPM.S6626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513216/
https://www.ncbi.nlm.nih.gov/pubmed/23226050
http://dx.doi.org/10.2147/PGPM.S6626

Ejemplares similares